Safety and Tolerability of Concomitant Administration of Multiple-Dose AM833 With Semaglutide 2.4 MG for Weight Management

Background: Combining weight management medications with different modes of action may provide more effective treatment options for people with obesity. Subcutaneous (sc) AM833, a long-acting amylin analog, and sc semaglutide 2.4 mg, a glucagon-like peptide-1 receptor agonist, are both under clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Enebo, Lone B, Berthelsen, Kasper K, Kankam, Martin, Lund, Michael T, Rubino, Domenica M, Satylganova, Altynai, Lau, David C W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Adipose Tissue, Appetite, and Obesity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089143/
http://dx.doi.org/10.1210/jendso/bvab048.051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089143/
http://dx.doi.org/10.1210/jendso/bvab048.051

Ejemplares similares